Pre-existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first-line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus-infected patients

Anna Kuznetsova; Aleksey Lebedev; Konstantin Gromov; Elena Kazennova; Maurizio Zazzi; Francesca Incardona; Anders Sönnerborg; Marina Bobkova

doi:10.1002/ccr3.5373

Pre-existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first-line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus-infected patients

Clin Case Rep. 2022 Feb 3;10(2):e05373. doi: 10.1002/ccr3.5373. eCollection 2022 Feb.

Authors

Anna Kuznetsova¹, Aleksey Lebedev¹, Konstantin Gromov¹, Elena Kazennova¹, Maurizio Zazzi², Francesca Incardona^{3

4}, Anders Sönnerborg⁵, Marina Bobkova¹

Affiliations

¹ Gamaleya Centre for epidemiology and microbiology Moscow Russia.
² University of Siena Siena Italy.
³ I-PRO Rome Italy.
⁴ EuResist Network Rome Italy.
⁵ Karolinska Institutet Stockholm Sweden.

Abstract

General consensus suggests that even singleton E138A mutations in HIV reverse transcriptase at baseline are associated with resistance to rilpivirine (RPV). We detected 11 pre-existing E138A carriers treated with RPV in the pan European EuResist database. However, all 11 patients presented with full virological efficacy for first-line RPV-based ART regimens.

Keywords: E138A; HIV; RPV; reverse transcriptase.

Publication types

Case Reports